The immune response to cytomegalovirus in allogeneic hematopoietic stem cell transplant recipients

被引:24
|
作者
Ciaurriz, Miriam [1 ]
Zabalza, Amaya [1 ,2 ]
Beloki, Lorea [1 ]
Mansilla, Cristina [1 ]
Perez-Valderrama, Estela [1 ]
Lachen, Mercedes [1 ]
Bandres, Eva [1 ,2 ,3 ]
Olavarria, Eduardo [1 ,4 ]
Ramirez, Natalia [1 ]
机构
[1] IDISNA Navarras Hlth Res Inst, Oncohematol Res Grp, Navarrabiomed Fdn Miguel Servet, Navarra 31008, Spain
[2] IDISNA, Navarra Hlth Serv, Complejo Hosp Navarra, Dept Hematol, Navarra, Spain
[3] Complejo Hospitalario Navarra, Immun Unit, Navarra Hlth Serv, IDISNA, Pamplona, Spain
[4] Imperial Coll Healthcare NHS, Hammersmith Hosp, London, England
关键词
CMV-specific T cells; Allogeneic HSCT; Immune monitoring; CD8(+) T-CELLS; BONE-MARROW TRANSPLANT; ENZYME-LINKED IMMUNOSPOT; IFN-GAMMA CD8(+); HUMAN NK CELLS; RISK-FACTORS; CMV INFECTION; LYMPHOCYTE RESPONSES; PREEMPTIVE THERAPY; IDENTIFY PATIENTS;
D O I
10.1007/s00018-015-1986-z
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Approximately, up to 70 % of the human population is infected with cytomegalovirus (CMV) that persists for life in a latent state. In healthy people, CMV reactivation induces the expansion of CMV-specific T cells up to 10 % of the entire T cell repertoire. On the contrary, CMV infection is a major opportunistic viral pathogen that remains a leading cause of morbidity and mortality after allogeneic hematopoietic stem cell transplantation. Due to the delayed CMV-specific immune recovery, the incidence of CMV reactivation during post-transplant period is very high. Several methods are currently available for the monitoring of CMV-specific responses that help in clinical monitoring. In this review, essential aspects in the immune recovery against CMV are discussed to improve the better understanding of the immune system relying on CMV infection and, thereby, helping the avoidance of CMV disease or reactivation following hematopoietic stem cell transplantation with severe consequences for the transplanted patients.
引用
收藏
页码:4049 / 4062
页数:14
相关论文
共 50 条
  • [31] Overview of cytomegalovirus viremia in allogeneic hematopoietic stem cell transplant recipients: Experience of a population with high seroprevalence
    Bourlon de los Rios, C.
    Vargas Serafin, C. O.
    Toledo Riquelme, A. K.
    BONE MARROW TRANSPLANTATION, 2022, 57 (SUPPL 1) : 294 - 295
  • [32] Neutrophils Response to Human CMV Reactivation in Allogeneic Hematopoietic Stem Cell Transplant Recipients
    Costa, Martina
    Tamassia, Nicola
    Ligozzi, Marco
    Marini, Olivia
    Cassatella, Marco
    Tecchio, Cristina
    BONE MARROW TRANSPLANTATION, 2020, 55 (SUPPL 1) : 479 - 479
  • [33] Vaccine response after pneumococcal vaccination in allogeneic hematopoietic stem cell transplant recipients
    Cheplowitz, Halle
    Patel, Nimish
    Kim, Alexander
    Logan, Cathy
    Law, Nancy
    Koura, Divya
    Haste, Nina
    Medley, Katherine
    Trinh, Julie
    Sanders, Tyler
    Taremi, Mahnaz
    Saunders, Ila M.
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2024, 30 (01) : 15 - 18
  • [34] Cellular Immune Response after Vaccination with an Adjuvanted, Recombinant Zoster Vaccine in Allogeneic Hematopoietic Stem Cell Transplant Recipients
    Koldehoff, Michael
    Horn, Peter A.
    Lindemann, Monika
    VACCINES, 2022, 10 (05)
  • [35] Preemptive Therapy for Cytomegalovirus Disease in Allogeneic Stem Cell Transplant Recipients
    de la Cruz-Vicente, F.
    Cerezuela Martinez, P.
    Gil-Esparraga, E.
    Martin Aguilera, C.
    Aguilar Guisado, M.
    Parody Ruiz-Berdejo, R.
    Cisneros Herreros, J. M.
    Urbano-Ispizua, A.
    Espigado Tocino, I.
    TRANSPLANTATION PROCEEDINGS, 2008, 40 (09) : 3102 - 3103
  • [36] Cidofovir for cytomegalovirus infection and disease in allogeneic stem cell transplant recipients
    Ljungman, P
    Deliliers, GL
    Platzbecker, U
    Matthes-Martín, S
    Bacigalupo, A
    Einsele, H
    Ullmann, J
    Musso, M
    Trenschel, R
    Ribaud, P
    Bornhäuser, M
    Cesaro, S
    Crooks, B
    Dekker, A
    Gratecos, N
    Klingebiel, T
    Tagliaferri, E
    Ullmann, AJ
    Wacker, P
    Cordonnier, C
    BLOOD, 2001, 97 (02) : 388 - 392
  • [37] EFFECTIVENESS OF LETERMOVIR FOR CYTOMEGALOVIRUS PROPHYLAXIS IN SEROPOSITIVE ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS: A GLOBAL SYSTEMATIC REVIEW
    Sepassi, A.
    Saunders, I
    Bounthavong, M.
    Watanabe, J.
    VALUE IN HEALTH, 2022, 25 (07) : S322 - S322
  • [38] How Should Cytomegalovirus Infection Be Managed in Allogeneic Hematopoietic Stem Cell Transplant Recipients? A Clinical Grand Round
    Nho, Dukhee
    Lee, Raeseok
    Cho, Sung-Yeon
    Lee, Dong-Gun
    INFECTION AND CHEMOTHERAPY, 2025, 57 (01): : 38 - 44
  • [39] Economic Burden of Cytomegalovirus Infection in Allogeneic Hematopoietic Stem Cell Transplant Recipients: A Spanish Multicenter, Retrospective Study
    Vazquez, Lourdes
    Sanz, Jaime
    Rovira, Montserrat
    Espigado, Ildefonso
    Rojas, Rafael
    Lopez, Javier
    Esquirol, Albert
    Bermudez, Maria Aranzazu
    De la Camara, Rafael
    Saldana, Raquel
    Inmaculada Heras, Maria
    Julia Gonzalez, Ana
    Batlle, Montserrat
    Torrado, Tamara
    Vallejo, Carlos
    Angeles Cuesta, Maria
    Barba, Pere
    Jimenez, Santiago
    Francisco Duarte, Rafael
    Tang, Yuexin
    Lozano, Virginia
    Maratia, Stefano
    Munoz, Alvaro
    Solano, Carlos
    BONE MARROW TRANSPLANTATION, 2020, 55 (SUPPL 1) : 399 - 400
  • [40] Monitoring of oral cytomegalovirus DNA shedding for the prediction of viral DNAemia in allogeneic hematopoietic stem cell transplant recipients
    Pascual, Tania
    Solano, Carlos
    Torres, Ignacio
    Talaya, Alberto
    Gimenez, Estela
    Vinuesa, Victor
    Pinana, Jose L.
    Hernandez-Boluda, Juan C.
    Perez, Ariadna
    Navarro, David
    JOURNAL OF MEDICAL VIROLOGY, 2018, 90 (08) : 1375 - 1382